Patrick Avenet

Author PubWeight™ 8.97^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.	Neuropsychopharmacology	2006	1.26
2	Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.	Neuropsychopharmacology	2005	1.24
3	SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.	Neuropsychopharmacology	2006	1.14
4	Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.	Neuropsychopharmacology	2007	1.08
5	The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.	Neuropsychopharmacology	2010	0.91
6	Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.	Pharmacol Biochem Behav	2008	0.89
7	SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.	CNS Drug Rev	2003	0.89
8	Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats.	Neuropharmacology	2013	0.84
9	Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?	Behav Pharmacol	2013	0.80